EULAR 2023: systemic lupus erythematosus
International EULAR Current
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Fanouriakis A, et al. Ann Rheum Dis. 2024;83:15–29
DOI 10.1136/ard-2023-224762 · Summary checked against the source: 2026-11
Citations give the level of evidence and grade, as written in the guideline (e.g. 1b/A), and the journal page. For kidney involvement, the 2025 EULAR update replaces recommendations 8–10 below: see EULAR 2025: lupus nephritis.
At a glance
- Hydroxychloroquine for everyone unless contraindicated, at 5 mg/kg real body weight/day. [1b/A · p. 17]
- Glucocorticoids: taper to ≤5 mg/day prednisone and stop if possible. IV methylprednisolone pulses (125–1000 mg/day for 1–3 days) for moderate–severe disease. [2a/B · p. 17]
- Not controlled on HCQ, or can't get steroids down: add methotrexate, azathioprine or mycophenolate, and/or belimumab or anifrolumab. [p. 17]
- Organ- or life-threatening disease: IV cyclophosphamide; rituximab if refractory. [2b/C · p. 17]
- Treat to target: remission (clinical SLEDAI 0 on HCQ, prednisone ≤5 mg) or low disease activity. [Figure 1 · p. 22]
- Thrombotic APS: long-term warfarin (vitamin K antagonist) after the first arterial or unprovoked venous event. High-risk aPL without APS: low-dose aspirin. [1b/B, 2a/B · p. 17]
Overarching principles
- A. Multidisciplinary, individualised care with patient education and shared decisions.
- B. Assess disease activity at every visit and organ damage at least yearly with validated tools (SLEDAI-2K, BILAG; SLICC damage index).
- C. Sun protection, no smoking (smoking reduces the effect of antimalarials and belimumab), diet, exercise and bone health.
- D. Drug choice depends on the organs involved, severity, harms, comorbidities and patient preference.
- E. Early diagnosis, regular screening for nephritis, treatment aiming at remission, and adherence prevent flares and damage.
Adapted from EULAR 2023 Table 1 [p. 16–17]
Recommendations
Every patient
- Hydroxychloroquine for all, unless contraindicated. [1b/A · p. 17] Target 5 mg/kg/day, adjusted for flare risk and retinal toxicity. [2b/B · p. 17] Don't stop it in remission: stopping raises the risk of flare. [p. 22]
- Glucocorticoids dosed by organ and severity [2b/C], reduced to ≤5 mg/day [2a/B] and withdrawn where possible.
- Vaccinate (herpes zoster, HPV, influenza, COVID-19, pneumococcus), protect bone, kidneys and CV health, and screen for cancer. [5/D · p. 17]
Escalation
Organ-specific treatment
| Manifestation | Treatment | Grade |
|---|---|---|
| Skin | Topical steroids or calcineurin inhibitors; antimalarials; systemic steroids if needed | 2b/B; 1a/A; 4/C |
| Second line: methotrexate, mycophenolate, anifrolumab, belimumab | 1b/B; 4/C; 1a/A; 1a/B | |
| Neuropsychiatric, inflammatory | Glucocorticoids + immunosuppressants | 1b/A |
| Neuropsychiatric, thrombotic or aPL-related | Antiplatelets or anticoagulants | 2b/C |
| Severe immune thrombocytopenia, acute | High-dose glucocorticoids (IV pulses) ± IVIG, and/or rituximab, and/or high-dose IV cyclophosphamide | 4/C; 4/C; 2b/B; 4/C |
| Thrombocytopenia, maintenance | Rituximab, azathioprine, mycophenolate or ciclosporin | 2b/B; 2b/C; 2b/C; 4/C |
| Thrombotic APS | Long-term vitamin K antagonist after the first arterial or unprovoked venous event | 1b/B |
| High-risk aPL, no thrombosis | Aspirin 75–100 mg/day | 2a/B |
Adapted from EULAR 2023 Table 1, recommendations 5–7 and 12 [p. 17]
Treating non-renal SLE
Mild: constitutional symptoms, mild arthritis, rash ≤9% body surface, platelets 50–100 × 10⁹/L, SLEDAI ≤6, ≤1 BILAG B.
| First line | HCQ ± short-course glucocorticoids |
| Second line | Methotrexate, azathioprine or mycophenolate; belimumab or anifrolumab |
Moderate: RA-like arthritis, rash 9–18%, platelets 20–50 × 10⁹/L, serositis, SLEDAI 7–12, ≥2 BILAG B.
| First line | HCQ + glucocorticoids, with methotrexate, azathioprine, mycophenolate or a calcineurin inhibitor; or belimumab or anifrolumab |
| Second line | Mycophenolate, calcineurin inhibitor, belimumab, anifrolumab |
Severe: major organ-threatening disease (cerebritis, myelitis, pneumonitis, mesenteric vasculitis), platelets <20 × 10⁹/L, TTP-like disease, haemophagocytic syndrome, rash >18%, SLEDAI >12, ≥1 BILAG A.
| First line | HCQ + glucocorticoids (IV pulses), with mycophenolate, cyclophosphamide or rituximab; belimumab or anifrolumab only for extensive skin or joint disease without major organ involvement |
| Second line | Cyclophosphamide or rituximab |
Target: remission (clinical SLEDAI 0, on HCQ, prednisone ≤5 mg/day) or low disease activity (SLEDAI ≤4, HCQ, prednisone ≤5 mg/day, stable tolerated immunosuppressants or biologics). Adapted from EULAR 2023 Figure 1 [p. 22]
Clinical pearls
- HCQ for every lupus patient, and keep it going in remission: stopping it raises the risk of flare.
- Anifrolumab blocks the type I interferon receptor; belimumab blocks BAFF (BLyS).
- APS: warfarin, not a DOAC, especially with arterial events or triple positivity.
- Remission = clinical SLEDAI 0 with prednisone ≤5 mg/day on HCQ.
Classes and levels of evidence
How EULAR SLE 2023 grades its recommendations. Adapted from EULAR SLE 2023 Table 1 (Oxford levels) [p. 17]. Hover over any class or level cited on this page to see what it means.
| LoE | Meaning | Wording used |
|---|---|---|
| LoE 1a | Systematic review of RCTs | |
| LoE 1b | Individual RCT | |
| LoE 2a | Systematic review of cohort studies | |
| LoE 2b | Individual cohort study, or a low-quality RCT | |
| LoE 3a | Systematic review of case-control studies | |
| LoE 3b | Individual case-control study | |
| LoE 4 | Case series, or poor-quality cohort or case-control studies | |
| LoE 5 | Expert opinion |
| Level | Meaning |
|---|---|
| GoR A | Based on consistent level 1 studies |
| GoR B | Based on consistent level 2 or 3 studies, or extrapolated from level 1 |
| GoR C | Based on level 4 studies, or extrapolated from level 2 or 3 |
| GoR D | Based on level 5 evidence, or troublingly inconsistent or inconclusive studies |
EULAR tags each recommendation with a level of evidence (LoE, 1a–5) and a grade of recommendation (GoR, A–D) from the Oxford Centre for Evidence-Based Medicine, written as "1b/A". Overarching principles carry no LoE. Each statement also has a level of agreement: the panel's mean score from 0 to 10.